510(k) device
NeuroStar TMS Therapy System
Neuronetics, Inc. · Transcranial Magnetic Stimulator (OBP, Class II) · First FDA decision Dec 16, 2008, newest Jul 15, 2022DepressionOCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
510(k) pathway
Device trials
35
Naming "NeuroStar TMS Therapy"
MAUDE reports
11
Brand "NeuroStar TMS Therapy", since 2015
PubMed studies
2
Mentioning "NeuroStar TMS Therapy"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NeuroStar TMS Therapy System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
K220127 · Decided Jul 15, 2022 · 178 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K213543 · Decided Dec 10, 2021 · 32 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K161519 · Decided Sep 11, 2016 · 101 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
3 more FDA decisions with a free account
Older decisions: K083538
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcranial Magnetic StimulationLocal determinationIn effectL33398Wellpoint FederalUpdated Jul 16, 2026
- Transcranial Magnetic StimulationProposed local determinationProposedDL33398National Government Services, Inc.Updated Mar 27, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL34641WPS Insurance CorporationUpdated Mar 20, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL37086Noridian Healthcare Solutions, LLCUpdated Aug 6, 2025
- Repetitive Transcranial Magnetic Stimulation (rTMS) in AdultsLocal determinationIn effectL34869Palmetto GBAUpdated Jan 7, 2025
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL36469CGS Administrators, LLCUpdated May 30, 2024
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "NeuroStar TMS Therapy", any status and sponsor, newest update first.
- Effects of rTMS on Cognitive Functions and Behavior in Individuals With Autism Spectrum DisorderRecruiting
King Saud UniversityAcademic, hospital or other
NCT06524310 · 80 participants (planned) · Start Jul 20, 2024 · Primary completion Apr 30, 2028
Device: Stimulation with low frequency rTMS at 1 Hz · For: Autism Spectrum Disorder
Sites: Riyadh, Saudi Arabia
- Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal DepressionActive, not recruiting
Rana JawishAcademic, hospital or other
NCT07928908 · 100 participants (planned) · Start Sep 23, 2026 · Primary completion Sep 2028
Device: Transcranial Magnetic Stimulation (TMS) · For: Perinatal Depression
Sites: Salt Lake City, Utah
- Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and AnxietyCompleted
Northwestern UniversityAcademic, hospital or other
NCT01701284 · 24 participants · Start Dec 2012 · Primary completion May 2023
Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · For: Cancer in Remission (Any Type or Stage); Depression; Anxiety
Sites: Chicago, Illinois
32 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NeuroStar TMS Therapy", and for the whole product code for context.
This brand
11 reports: 1 malfunction, 10 injury, 0 death
Whole product code OBP
337 reports: 9 malfunction, 323 injury, 2 death
Newest reports for this brand
MW5187360 · Received Apr 28, 2026 · Event dated Dec 10, 2024
Device type: Transcranial Magnetic Stimulator (OBP)
Patient problem as coded: Headache; Hypersensitivity/Allergic reaction; Pain; Discomfort; Eye Pain
MW5162644 · Received Nov 18, 2024
Device type: Transcranial Magnetic Stimulator (OBP)
Patient problem as coded: Emotional Changes; Headache; Pain; Twitching; Anxiety; Irritability; Unspecified Mental, Emotional or Behavioral Problem
MW5115632 · Received Mar 9, 2023 · Event dated Jan 30, 2023
Device type: Transcranial Magnetic Stimulator (OBP)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Headache; Nausea; Vertigo; Twitching; Sleep Dysfunction
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "NeuroStar TMS Therapy"[tiab]. The summary above synthesizes these.
- Transcranial magnetic stimulation in depression--lessons from the multicentre trials.
Schönfeldt-Lecuona C, Cárdenas-Morales L, Freudenmann RW, et al. · Restor Neurol Neurosci · 2010Research Support, Non-U.S. Gov't, Review
- Transcranial magnetic stimulation for major depressive disorder: a pragmatic approach to implementing TMS in a clinical practice.
Derstine T, Lanocha K, Wahlstrom C, et al. · Ann Clin Psychiatry · 2010Case Reports, Review
Other devices of this type
Also filed under product code OBP.
- BrainsWay Deep TMS SystemBrainsway , Ltd. · 510(k) 2025
- Apollo TMS Therapy SystemMag & More GmbH · 510(k) 2026
- MagVita TMS Therapy w/MagPro R20Tonica Elektronik A/S · 510(k) 2017
- NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 510(k) 2024
- Magstim Horizon 3.0 TMS Therapy SystemMagstim Company, Ltd. · 510(k) 2023
- HORIZON TMS Therapy System with NavigationMagstim Company, Ltd. · 510(k) 2019
- Nexstim Navigated Brain Stimulation (NBS) 6 System (NBS6)Nexstim Oyj · 510(k) 2026
- MagVenture TMS Therapy SystemTonica Elektronik A/S · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.